Nektar Therapeutics

NASDAQ: NKTR
$3.46
+$0.00 (+0.0%)
Closing price May 26, 2022
Monday’s additional top analyst upgrades and downgrades included Aptiv, BioCryst Pharmaceuticals, CSX, Gap, Nektar Therapeutics, Progressive, Peloton Interactive, Sirius XM and United Airlines.
Tuesday afternoon's top analyst upgrades and downgrades included Coupa Software, GoodRx, Mosaic and Nektar Therapeutics.
Wednesday afternoon's top analyst upgrades and downgrades included Bumble, Coupang, Foot Locker, Gap, Match, Nektar Therapeutics, Paychex, Signify Health and Stitch Fix.
Tuesday’s top analyst upgrades and downgrades included Bloomin' Brands, Boston Beer, Bumble, Goldman Sachs, Juniper Networks, Merck, Moderna, Petco Health, Southern Company, Spirit Airlines and...
Tuesday's top analyst upgrades and downgrades included Airbnb, Canopy Growth, Continental Resources, DraftKings, Fisker, Moderna, Owens Corning, SunPower and Wayfair.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
Monday’s top analyst upgrades and downgrades included GoDaddy, Groupon, Resmed, Salesforce, Shopify, Squarespace, Yelp, and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including BioNTech, Denali Therapeutics, Exelixis, Foot Locker and Hostess Brands.
Monday's top analyst upgrades and downgrades included Alphabet, Amazon.com, Amgen, Cerner, eBay, Gap, Nike, Nucor, Procter & Gamble, TJX and ViacomCBS.
Wednesday's top analyst upgrades, downgrades and initiations included Altria, Beyond Meat, Chevron, Chipotle Mexican Grill, Epizyme, FedEx, Home Depot, Mattel, Morgan Stanley, Oracle, Qualcomm and...
Monday's top analyst upgrades, downgrades and initiations included Aimmune Therapeutics, Amgen, Biogen, Chevron, CRISPR, Exxon Mobil, Nike, Snap, Uber, Ulta Beauty and Verizon.
This past week played host to a huge number of biotech movers. 24/7 Wall St. has picked a few of these standouts to highlight.
Nektar Therapeutics shares were crushed on Wednesday after the FDA did not recommend the company’s pain drug.
Nektar Therapeutics shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune and other chronic...
Tuesday's top analyst upgrades, downgrades and initiations included Apollo Global Management, BlackRock, Cloudflare, Green Plains, Microsoft, Oracle, Target and TJX Companies.